Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

BMS scientists report new dual-action NK-1 antagonists/5-HT reuptake inhibitors

Feb. 23, 2009

Eisai and Bial partner for European commercialization of Zebinix

Feb. 20, 2009

sanofi-aventis imparts new cannabinoid CB2 receptor antagonists for pain relief

Feb. 20, 2009

New gamma-secretase inhibitors reported in recent Schering-Plough patent

Feb. 20, 2009

AVI BioPharma treats first patient in AVI-4658 Duchenne muscular dystrophy trial

Feb. 20, 2009

TRPV1-mediated analgesic activity is enhanced by repeated administration of ABT-102

Feb. 20, 2009

FDA extends Hemispherx's NDA review date for Ampligen in CFS

Feb. 19, 2009

FDA sets PDUFA date for review of Zogenix's NDA for migraine drug Sumavel DosePro

Feb. 19, 2009

Phase III SOFIA study does not achieve primary endpoint in autistic disorder

Feb. 19, 2009

Pharmos agrees to sell PRS-639058 and other CB2 agonists to Reperio

Feb. 19, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...